Project
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL,
Automatically Closed ยท 2019 until 2022
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Status
Automatically Closed
Start Date
2019
End Date
2022
Financing
Industry
Study Design
Phase IIi - Studie
Brief description/objective
Palliative systemic treatment option in Her2 low patients
after one, max. 2 chemotherapy lines